<p>Clearside Biomedical（納斯達克代碼：CLSD - 獲取免費報告）的股票在 Needham &amp; Company LLC 發佈的一份報告中重申了 “買入” 評級，Benzinga 報道。它們目前對該股票的目標價為 4.00 美元。Needham &amp; Company LLC 的目標價意味着該股票相較於之前的收盤價有 373.20% 的潛在上漲空間。</p>
<p>獲取 <strong>Clearside Biomedical</strong> 的提醒：</p>
<p>CLSD 已經成為其他多份報告的主題。HC Wainwright 在 3 月 31 日的研究報告中重申了 “買入” 評級，並對 Clearside Biomedical 的股票設定了 6.00 美元的目標價。StockNews.com 在 3 月 18 日的研究報告中將 Clearside Biomedical 的股票評級從 “持有” 下調至 “賣出”。最後，Chardan Capital 在 3 月 28 日的報告中重申了 “買入” 評級，並對 Clearside Biomedical 的股票設定了 6.00 美元的目標價。一位分析師對該股票給予了賣出評級，而四位分析師則給予了買入評級。根據 MarketBeat.com 的數據，Clearside Biomedical 目前的共識評級為 “適度買入”，平均目標價為 5.25 美元。</p>
<p><strong>查看我們最新的 CLSD 股票報告</strong></p>
<h2>Clearside Biomedical 股票表現</h2>
<p>CLSD 的股票在週二開盤價為 0.85 美元。Clearside Biomedical 的 1 年最低價為 0.77 美元，1 年最高價為 1.65 美元。該股票的市值為 6521 萬美元，市盈率為-1.88，貝塔係數為 2.04。公司的 50 日移動平均線為 0.96 美元，200 日移動平均線為 1.03 美元。</p>
<p>Clearside Biomedical（納斯達克代碼：CLSD - 獲取免費報告）最近在 3 月 27 日發佈了季度財報。該公司報告每股收益（EPS）為-0.10 美元，超出市場共識預期的-0.13 美元，超出幅度為 0.03 美元。該公司本季度的收入為 31 萬美元，而分析師預期為 27 萬美元。賣方分析師預測 Clearside Biomedical 在當前年度的每股收益將為-0.48 美元。</p>
<h2>對 Clearside Biomedical 的對沖基金看法</h2>
<p>對沖基金和其他機構投資者最近調整了對該公司的持股。投資者 Fiduciary Advisor Network LLC 在第四季度收購了 Clearside Biomedical 的新股份，價值約為 32,000 美元。Northern Trust Corp 在第四季度將其在 Clearside Biomedical 的持股增加了 24.0%。Northern Trust Corp 目前擁有 165,499 股該公司的股票，價值 157,000 美元，此前在上個季度又購買了 32,048 股。最後，Geode Capital Management LLC 在第四季度將其在 Clearside Biomedical 的股份增加了 4.5%。Geode Capital Management LLC 目前擁有 764,058 股該公司的股票，價值 726,000 美元，此前在該期間又購買了 32,672 股。機構投資者和對沖基金持有該公司 18.75% 的股份。</p>
<h2>Clearside Biomedical 公司簡介</h2>
<p>（獲取免費報告）</p>
<p>Clearside Biomedical, Inc 是一家生物製藥公司，專注於通過脈絡膜上腔革命性地輸送治療藥物到眼後部。它提供 XIPERE，一種用於治療葡萄膜炎性黃斑水腫的三氟氯噻噸脈絡膜上腔注射懸液。它還開發 CLS-AX，一種用於脈絡膜上腔注射的阿昔替尼注射懸液，目前正在進行 IIb 期臨牀試驗，以治療濕性年齡相關性黃斑變性。</p>
<h2>瞭解更多</h2>
<ul>
<li>我們更看好的五隻股票比 Clearside Biomedical 更好</li>
<li>股票平均計算器</li>
<li>PayPal 股票：太便宜而無法忽視，太強大而無法錯過</li>
<li>如何利用分析師評級進行交易</li>
<li>Progress Software：在 AI 革命的推動下取得進展</li>
<li>深入瞭解買賣差價</li>
<li>英特爾 - 台灣半導體聯盟激發復甦希望</li>
</ul>
<p><em>此即時新聞提醒由敍事科學技術和 MarketBeat 的金融數據生成，以便為讀者提供最快和最準確的報道。此故事在發佈前已由 MarketBeat 的編輯團隊審核。如對該故事有任何問題或意見，請發送郵件至 contact@marketbeat.com。</em></p>
<h2>你現在應該投資 1,000 美元在 Clearside Biomedical 嗎？</h2>
<p>在你考慮 Clearside Biomedical 之前，你需要聽聽這個。</p>
<p>MarketBeat 每天跟蹤華爾街頂級評級和表現最佳的研究分析師及其推薦給客户的股票。MarketBeat 已識別出五隻頂級分析師悄悄向客户推薦的股票，建議在更廣泛的市場注意到之前購買……而 Clearside Biomedical 並不在名單上。</p>
<p>雖然 Clearside Biomedical 目前在分析師中獲得了買入評級，但頂級分析師認為這五隻股票更值得購買。</p>
<p>在這裏查看這五隻股票</p>

Clearside生物醫學

CLSDQ

<p>Needham & Company LLC 重申了對 Clearside Biomedical (NASDAQ:CLSD) 的 “買入” 評級，目標價為 4.00 美元，意味着潛在上漲空間為 373.20%。其他分析師也對該股票進行了評級，HC Wainwright 和 Chardan Capital 設定的目標價為 6.00 美元。Clearside Biomedical 的股票開盤價為 0.85 美元，市值為 6521 萬美元。該公司報告每股收益為（0.10）美元，超出預期。機構投資者持有該股票的 18.75%，該公司專注於提供眼部疾病的治療方案</p>

<p>Clearside Biomedical (NASDAQ:CLSD - Get Free Report)'s stock had its &#34;buy&#34; rating reiterated by stock analysts at Needham &amp; Company LLC in a report released on Tuesday,Benzinga reports. They currently have a $4.00 price objective on the stock. Needham &amp; Company LLC's target price points to a potential upside of 373.20% from the stock's previous close.</p>
<div class="lb-trans"><p>Clearside Biomedical（納斯達克代碼：CLSD - 獲取免費報告）的股票在 Needham &amp; Company LLC 發佈的一份報告中重申了 “買入” 評級，Benzinga 報道。它們目前對該股票的目標價為 4.00 美元。Needham &amp; Company LLC 的目標價意味着該股票相較於之前的收盤價有 373.20% 的潛在上漲空間。</p>
</div><p>Get <strong>Clearside Biomedical</strong> alerts:</p>
<div class="lb-trans"><p>獲取 <strong>Clearside Biomedical</strong> 的提醒：</p>
</div><p>CLSD has been the topic of a number of other reports. HC Wainwright restated a &#34;buy&#34; rating and issued a $6.00 price target on shares of Clearside Biomedical in a research note on Monday, March 31st. StockNews.com lowered shares of Clearside Biomedical from a &#34;hold&#34; rating to a &#34;sell&#34; rating in a research report on Tuesday, March 18th. Finally, Chardan Capital reiterated a &#34;buy&#34; rating and issued a $6.00 price target on shares of Clearside Biomedical in a report on Friday, March 28th. One analyst has rated the stock with a sell rating and four have given a buy rating to the company's stock. According to data from MarketBeat.com, Clearside Biomedical currently has a consensus rating of &#34;Moderate Buy&#34; and an average price target of $5.25.</p>
<div class="lb-trans"><p>CLSD 已經成為其他多份報告的主題。HC Wainwright 在 3 月 31 日的研究報告中重申了 “買入” 評級，並對 Clearside Biomedical 的股票設定了 6.00 美元的目標價。StockNews.com 在 3 月 18 日的研究報告中將 Clearside Biomedical 的股票評級從 “持有” 下調至 “賣出”。最後，Chardan Capital 在 3 月 28 日的報告中重申了 “買入” 評級，並對 Clearside Biomedical 的股票設定了 6.00 美元的目標價。一位分析師對該股票給予了賣出評級，而四位分析師則給予了買入評級。根據 MarketBeat.com 的數據，Clearside Biomedical 目前的共識評級為 “適度買入”，平均目標價為 5.25 美元。</p>
</div><p><strong>View Our Latest Stock Report on CLSD</strong></p>
<div class="lb-trans"><p><strong>查看我們最新的 CLSD 股票報告</strong></p>
</div><h2>Clearside Biomedical Stock Performance</h2>
<div class="lb-trans"><h2>Clearside Biomedical 股票表現</h2>
</div><p>Shares of CLSD opened at $0.85 on Tuesday. Clearside Biomedical has a 1 year low of $0.77 and a 1 year high of $1.65. The stock has a market capitalization of $65.21 million, a P/E ratio of -1.88 and a beta of 2.04. The company's fifty day moving average is $0.96 and its two-hundred day moving average is $1.03.</p>
<div class="lb-trans"><p>CLSD 的股票在週二開盤價為 0.85 美元。Clearside Biomedical 的 1 年最低價為 0.77 美元，1 年最高價為 1.65 美元。該股票的市值為 6521 萬美元，市盈率為-1.88，貝塔係數為 2.04。公司的 50 日移動平均線為 0.96 美元，200 日移動平均線為 1.03 美元。</p>
</div><p>Clearside Biomedical (NASDAQ:CLSD - Get Free Report) last posted its quarterly earnings results on Thursday, March 27th. The company reported ($0.10) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.13) by $0.03. The firm had revenue of $0.31 million for the quarter, compared to analysts' expectations of $0.27 million. Sell-side analysts predict that Clearside Biomedical will post -0.48 EPS for the current year.</p>
<div class="lb-trans"><p>Clearside Biomedical（納斯達克代碼：CLSD - 獲取免費報告）最近在 3 月 27 日發佈了季度財報。該公司報告每股收益（EPS）為-0.10 美元，超出市場共識預期的-0.13 美元，超出幅度為 0.03 美元。該公司本季度的收入為 31 萬美元，而分析師預期為 27 萬美元。賣方分析師預測 Clearside Biomedical 在當前年度的每股收益將為-0.48 美元。</p>
</div><h2>Hedge Funds Weigh In On Clearside Biomedical</h2>
<div class="lb-trans"><h2>對 Clearside Biomedical 的對沖基金看法</h2>
</div><p>Hedge funds and other institutional investors have recently modified their holdings of the company. Investor s Fiduciary Advisor Network LLC acquired a new stake in Clearside Biomedical during the fourth quarter valued at approximately $32,000. Northern Trust Corp grew its holdings in Clearside Biomedical by 24.0% during the fourth quarter. Northern Trust Corp now owns 165,499 shares of the company's stock valued at $157,000 after purchasing an additional 32,048 shares during the last quarter. Finally, Geode Capital Management LLC increased its stake in shares of Clearside Biomedical by 4.5% in the fourth quarter. Geode Capital Management LLC now owns 764,058 shares of the company's stock worth $726,000 after purchasing an additional 32,672 shares during the period. Institutional investors and hedge funds own 18.75% of the company's stock.</p>
<div class="lb-trans"><p>對沖基金和其他機構投資者最近調整了對該公司的持股。投資者 Fiduciary Advisor Network LLC 在第四季度收購了 Clearside Biomedical 的新股份，價值約為 32,000 美元。Northern Trust Corp 在第四季度將其在 Clearside Biomedical 的持股增加了 24.0%。Northern Trust Corp 目前擁有 165,499 股該公司的股票，價值 157,000 美元，此前在上個季度又購買了 32,048 股。最後，Geode Capital Management LLC 在第四季度將其在 Clearside Biomedical 的股份增加了 4.5%。Geode Capital Management LLC 目前擁有 764,058 股該公司的股票，價值 726,000 美元，此前在該期間又購買了 32,672 股。機構投資者和對沖基金持有該公司 18.75% 的股份。</p>
</div><h2>Clearside Biomedical Company Profile</h2>
<div class="lb-trans"><h2>Clearside Biomedical 公司簡介</h2>
</div><p>(Get Free Report)</p>
<div class="lb-trans"><p>（獲取免費報告）</p>
</div><p>Clearside Biomedical, Inc, a biopharmaceutical company, focuses on the revolutionizing the delivery of therapies to the back of the eye through the suprachoroidal space. It offers XIPERE, a triamcinolone acetonide suprachoroidal injectable suspension for the treatment of uveitis macular edema. It also develops CLS-AX, an axitinib injectable suspension for suprachoroidal injection, which is in Phase IIb clinical trial to treat wet AMD.</p>
<div class="lb-trans"><p>Clearside Biomedical, Inc 是一家生物製藥公司，專注於通過脈絡膜上腔革命性地輸送治療藥物到眼後部。它提供 XIPERE，一種用於治療葡萄膜炎性黃斑水腫的三氟氯噻噸脈絡膜上腔注射懸液。它還開發 CLS-AX，一種用於脈絡膜上腔注射的阿昔替尼注射懸液，目前正在進行 IIb 期臨牀試驗，以治療濕性年齡相關性黃斑變性。</p>
</div><h2>Read More</h2>
<div class="lb-trans"><h2>瞭解更多</h2>
</div><ul>
<li>Five stocks we like better than Clearside Biomedical</li>
<li>Stock Average Calculator</li>
<li>PayPal Stock: Too Cheap to Ignore, Too Strong to Miss</li>
<li>How to trade using analyst ratings</li>
<li>Progress Software: Making Progress Driven by the AI Revolution</li>
<li>A Deeper Look at Bid-Ask Spreads</li>
<li>Intel-Taiwan Semiconductor Alliance Fuels Turnaround Hopes</li>
</ul>
<div class="lb-trans"><ul>
<li>我們更看好的五隻股票比 Clearside Biomedical 更好</li>
<li>股票平均計算器</li>
<li>PayPal 股票：太便宜而無法忽視，太強大而無法錯過</li>
<li>如何利用分析師評級進行交易</li>
<li>Progress Software：在 AI 革命的推動下取得進展</li>
<li>深入瞭解買賣差價</li>
<li>英特爾 - 台灣半導體聯盟激發復甦希望</li>
</ul>
</div><p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即時新聞提醒由敍事科學技術和 MarketBeat 的金融數據生成，以便為讀者提供最快和最準確的報道。此故事在發佈前已由 MarketBeat 的編輯團隊審核。如對該故事有任何問題或意見，請發送郵件至 contact@marketbeat.com。</em></p>
</div><h2>Should You Invest $1,000 in Clearside Biomedical Right Now?</h2>
<div class="lb-trans"><h2>你現在應該投資 1,000 美元在 Clearside Biomedical 嗎？</h2>
</div><p>Before you consider Clearside Biomedical, you'll want to hear this.</p>
<div class="lb-trans"><p>在你考慮 Clearside Biomedical 之前，你需要聽聽這個。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Clearside Biomedical wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟蹤華爾街頂級評級和表現最佳的研究分析師及其推薦給客户的股票。MarketBeat 已識別出五隻頂級分析師悄悄向客户推薦的股票，建議在更廣泛的市場注意到之前購買……而 Clearside Biomedical 並不在名單上。</p>
</div><p>While Clearside Biomedical currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>雖然 Clearside Biomedical 目前在分析師中獲得了買入評級，但頂級分析師認為這五隻股票更值得購買。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>在這裏查看這五隻股票</p>
</div>

Needham & Company LLC 重申對 Clearside Biomedical (NASDAQ:CLSD) 的 “買入” 評級